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behalf of the UK Collaborative HIV Cohort (CHIC)/CKD Study Group*
Background: Chronic kidney disease (CKD) is associated with increased all-cause mortality and kidney
disease progression. Decreased kidney function at baseline may identify human immunodeficiency virus
(HIV)-positive patients at increased risk of death and kidney disease progression.
Study Design: Observational cohort study.
Setting & Participants: 7 large HIV cohorts in the United Kingdom with kidney function data available for
20,132 patients.
Predictor: Baseline estimated glomerular filtration rate (eGFR).
Outcomes: Death and progression to stages 4-5 CKD (eGFR 30 mL/min/1.73 m2 for 3 months) in Cox
proportional hazards and competing-risk regression models.
Results: Median age at baseline was 34 (25th-75th percentile, 30-40) years, median CD4 cell count was 350
(25th-75th percentile, 208-520) cells/L, and median eGFR was 100 (25th-75th percentile, 87-112) mL/min/
1.73 m2. Patients were followed up for a median of 5.3 (25th-75th percentile, 2.0-8.9) years, during which 1,820
died and 56 progressed to stages 4-5 CKD. A U-shaped relationship between baseline eGFR and mortality was
observed. After adjustment for potential confounders, eGFRs 45 and 105 mL/min/1.73 m2 remained
associated significantly with increased risk of death. Baseline eGFR90 mL/min/1.73 m2 was associated with
increased risk of kidney disease progression, with the highest incidence rates of stages 4-5 CKD (3
events/100 person-years) observed in black patients with eGFR of 30-59 mL/min/1.73 m2 and those of
white/other ethnicity with eGFR of 30-44 mL/min/1.73 m2.
Limitations: The relatively small numbers of patients with decreased eGFR at baseline and low rates of
progression to stages 4-5 CKD and lack of data for diabetes, hypertension, and proteinuria.
Conclusions: Although stages 4-5 CKD were uncommon in this cohort, baseline eGFR allowed the
identification of patients at increased risk of death and at greatest risk of kidney disease progression.
INDEX WORDS: Estimated glomerular filtration rate (eGFR); Chronic Kidney Disease Epidemiology Collabo-
ration (CKD-EPI); human immunodeficiency virus (HIV); chronic kidney disease; mortality; competing risk.
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nodeficiency virus (HIV) infection, with dramatic
decreases in the incidence of AIDS and death.1,2 In
the developed world, the majority of deaths now are
the result of nonopportunistic infections, atheroscle-
rotic cardiovascular disease, liver and kidney disease,
and non-AIDS malignancies.3,4 The prevalence of
subclinical atherosclerosis and kidney disease is in-
creased in HIV-positive patients.5-10 Although HIV-
associated nephropathy is associated with high rates
of kidney disease progression,11-13 HIV-induced im-
mune dysregulation, inflammation, thrombotic activ-
ity, and cART toxicity may all contribute to acceler-
ated atherosclerosis and kidney disease progression in
this population.14-18
In the general population, proteinuria and de-
creased estimated glomerular filtration rate (eGFR)
are risk factors for death and cardiovascular dis-
ease.19-22 In patients with stages 2-4 chronic kidney
disease (CKD), the risk of death is much greater than
the risk of developing end-stage renal disease.23 In
HIV-positive patients, CKD similarly is associated
Am J Kidney Dis. 2012;60(4):539-547with cardiovascular disease24-26 and increased risk of
death,27-31 although the rate of progression to end-
stage renal disease may be considerably higher in
those of black ethnicity.32,33 The competing risks of
mortality and kidney disease progression may differ
in general and HIV-positive populations and, in the
latter, by ethnicity. The aims of the present study were
to examine the effect of baseline eGFR on all-cause
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Ibrahim et almortality in a large HIV cohort in the United King-
dom and assess the risk of progression to stages 4-5
CKD while accounting for the competing risk of
all-cause mortality.
METHODS
StudyPopulation andMeasurements
Data were obtained from the UK Collaborative HIV Cohort
(CHIC) Study.34 UK CHIC is an observational cohort study of
HIV-positive individuals 16 years and older who have attended
some of the largest HIV clinics in the United Kingdom at least
once since January 1996. It is approved by the National Health
Service Multi-Centre Research Ethics Committee. The present
analyses include data up to December 2008 and were restricted to 7
centers that routinely contributed serum creatinine data. Informa-
tion from the Office of National Statistics death register was used
to ensure optimal ascertainment of deaths for patients who became
lost to follow-up. Until recently, there was little recognition of the
contribution of HIV or cART to non-AIDS outcomes; data for
hypertension and diabetes therefore were not recorded. Similarly,
data for proteinuria were not collected routinely and thus were not
included in the present analyses to avoid the introduction of bias.
All available serum creatinine values were converted to eGFR using
the CKD-EPI (CKD Epidemiology Collaboration) equation35,36:
141min(SCr/, 1)max(SCr/, 1)1.209 0.993Age 1.018
[if female]  1.159 [if black], where SCr is serum creatinine (in
milligrams per deciliter; Jaffé creatinine values were converted to
isotope-dilution mass spectrometry–traceable values by multiply-
ing by 0.95 as per Levey et al37);  is 0.7 if female or 0.9 if male; 
is 0.329 if female or 0.411 if male; min is the minimum of
SCr/ or 1; and max is the maximum of SCr/ or 1.
Mortality and progression to stages 4-5 CKD (eGFR 30
mL/min/1.73 m2 for 3 months) were analyzed in patients strati-
fied by baseline kidney function. Because acute renal failure is
particularly common within 3 months of HIV diagnosis38 and the
greatest changes in kidney function are observed soon after start-
ing cART,39 baseline kidney function was defined as the first
available eGFR that was determined more than 3 months after the
time of cohort entry.
Statistical Analysis
Data were analyzed using STATA (version 11; Stata Corp,
www.stata.com). Person-years of follow-up were calculated from
the date of baseline eGFR to the date of death or censoring (last
clinic visit or December 31, 2008, whichever came first). Baseline
parameters were compared using 2, Fisher exact, or Kruskal-
Wallis tests, as appropriate. Because of a significant interaction
between ethnicity and eGFR (P  0.001), analyses also were
stratified by ethnicity (black vs white/other).
Cox proportional hazards regression models were used to exam-
ine associations between baseline eGFR and all-cause mortality,
with graphical checks and Schoenfeld residual testing for the final
Cox model to confirm proportionality. Baseline eGFR was strati-
fied into 6 categories (105, 90-104, 60-89, 45-59, 30-44 and30
mL/min/1.73 m2)40 and modeled as continuous piecewise linear
splines with knots at 45, 60, 75, 90, and 105 mL/min/1.73 m2.21
Multivariable models were adjusted for both fixed covariates,
assessed at the time of baseline eGFR (age at cohort entry, sex,
HIV exposure group, and year of cohort entry) and time-updated
covariates (AIDS, CD4 cell count, HIV RNA [500 vs 500
copies/mL], hepatitis B and C status, and cART use [no/yes]). We
took an intention-to-continue cART approach and ignored subse-
quent treatment interruptions. Complete or near-complete data
were available for all covariates except HIV exposure group and
540hepatitis B and hepatitis C status. Our analyses used a missing-
indicator approach to deal with missing data; thus, all patients were
included in the analyses.
Competing-risk regression models41,42 were used to investigate
associations between baseline kidney function and progression to
stages 4-5 CKD because death and kidney disease progression are
competing outcomes in the general CKD population.43 Competing-
risk models provide estimations of subhazard ratios, which can be
interpreted similarly to hazard ratios generated by standard Cox
regression analyses. Subhazard ratios were adjusted for age at
entry, sex, HIV exposure group, year of cohort entry, AIDS, CD4
cell count, HIV RNA (500 vs 500 copies/mL), hepatitis B and
C status, and cART use (no/yes), all as fixed covariates assessed at
the time of baseline eGFR. To preserve power with enough events
in each category, eGFR was stratified into 4 categories (90,
60-89, 45-59 and 30-44 mL/min/1.73 m2). Robust standard errors
were used to account for the cluster effect, and all statistical tests
were 2 sided.
RESULTS
BaselineCharacteristics
Of 27,577 patients who received care during the
study period, 5,119 (19%) had no kidney function
data and 2,326 (8%) died or were lost to follow-up
within 3 months of cohort entry; the remaining 20,132
(73%) were included in analyses (Fig 1). Patients
without kidney function data had similar CD4 cell
counts at baseline but were more likely to be male,
have MSM or IVDU (men who have sex with men
and intravenous drug use) as risk factors for HIV
acquisition, and have a lower prevalence of viral
hepatitis (B and C) coinfection compared with those
included in the analyses (data not shown). Baseline
eGFR was assessed at a median of 4 (25th-75th
percentile, 3-13) months from cohort entry and 5
(25th-75th percentile, 3-13) months from HIV diagno-
sis. At baseline, median age was 34 (25th-75th percen-
tile, 30-40) years, median CD4 cell count was 350
(25th-75th percentile, 208-520) cells/L, median
eGFR was 100 (25th-75th percentile, 87-112) mL/min/
1.73 m2, and 80% of patients had commenced cART.
Table 1 lists patient characteristics stratified by base-
Eligible paents 
N=27,577 
Creanine 
N=22,458 
No creanine 
N=5,119 
CKD-EPI derived eGFR 
N=20,132 
Excluded from the current analysis  
N=2,326 
Figure 1. Disposition of patients for the all-cause mortality
and chronic kidney disease progression analyses. Abbrevia-
tions: CKD-EPI, Chronic Kidney Disease Epidemiology Collabo-
ration; eGFR, estimated glomerular filtration rate.line eGFR. Younger, black, and female patients were
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Table 1. Baseline Characteristics in Patients Stratified by eGFR Category
Variable
eGFR Category (mL/min/1.73 m2)
P>105 (n  8,307; 41%) 104-90 (n 5,951; 30%) 89-60 (n 5,466; 27%) 59-45 (n  256; 1.3%) 44-30 (n 65; 0.3%) <30 (n  87; 0.4%)
Age at cohort entry (y) 32 [28, 36] 35 [30, 41] 38 [33, 46] 44 [36, 54] 41 [35, 50] 38 [33, 45] 0.001
Sex 0.001
Female 2,156 (26.0) 1,036 (17.0) 1,015 (18.6) 54 (21.1) 19 (29.2) 37 (42.5)
Male 6,151 (74.0) 4,915 (83.0) 4,451 (81.4) 202 (78.9) 46 (70.8) 50 (57.5)
Ethnicity 0.001
Black 2,838 (34.2) 1,158 (19.5) 877 (16.0) 50 (19.5) 25 (38.5) 54 (62.1)
White/other 5,469 (65.8) 4,793 (80.5) 4,589 (84.0) 206 (80.5) 40 (61.5) 33 (37.9)
Risk group 0.001
IVDU/other 800 (9.6) 412 (6.9) 325 (6.0) 23 (9.0) 7 (10.8) 16 (18.4)
MSM 4,402 (53.0) 3,871 (65.0) 3,503 (64.1) 131 (51.2) 23 (35.4) 15 (17.2)
Heterosexual 2,786 (33.5) 1,433 (24.1) 1,334 (24.4) 73 (28.5) 30 (46.2) 53 (60.9)
HBsAg 449 (5.4) 327 (5.5) 275 (5.0) 9 (3.5) 1 (1.5) 3 (3.4) 0.4
HCV Ab 634 (7.6) 486 (8.2) 407 (7.5) 21 (8.2) 4 (6.2) 1 (1.1) 0.1
AIDSa 2,222 (26.7) 1,746 (29.3) 1,720 (31.5) 107 (41.8) 26 (40.0) 34 (39.1) 0.001
CD4 cell count (cells/L) 350 [206, 518] 360 [217, 532] 334 [196, 511] 220 [130, 383] 160 [84, 289] 202 [96, 330] 0.001
HIV RNA (copies/mL) 6,622 [184, 50,500] 8,380 [326, 57,000] 5,147 [200, 46,000] 822 [50, 28,330] 500 [50, 46,000] 577 [50, 59,065] 0.001
Initiated cART 6,545 (78.8) 4,714 (79.2) 4,487 (82.1) 220 (85.9) 56 (86.2) 77 (88.5) 0.001
Note: Continuous variables given as median [25th, 75th percentile]; categorical variables given as number (column percentage). P values are unadjusted, using 2 tests for difference in
proportions and Kruskal-Wallis tests for difference in median values.
Abbreviations and definitions: cART, combination antiretroviral therapy; eGFR, estimated glomerular filtration rate; HBsAg, hepatitis B surface antigen positive; HCV Ab, hepatitis C
antibody positive; HIV, human immunodeficiency virus; IVDU, intravenous drug use; MSM, men who have sex with men.
aPer Centers for Disease Control and Prevention classification system for HIV-infected adults and adolescents.
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Ibrahim et alover-represented in those with eGFR 30 mL/min/
1.73 m2. When stratified by ethnicity, there were more
women (57%) in the black patients; 90% of white/
other patients were male, the majority of whom had
acquired HIV infection through sex between men.
Black patients were younger (median age, 33 vs 35
years), less likely to be coinfected with hepatitis C
(2.1% vs 9.6%), and had lower median CD4 cell
counts (280 vs 370 cells/L). Although black patients
had a higher median eGFR compared with those of
white/other ethnicity (109 vs 98 mL/min/1.73 m2), a
greater proportion of black patients (1.1% vs 0.2%)
had eGFR30 mL/min/1.73 m2 at baseline.
Baseline eGFRandAll-CauseMortality
Patients were followed up for a median of 5.3
(25th-75th percentile, 2.0-8.9) years, during which
1,820 patients (295 black and 1,525 white/other) died.
The crude mortality rate in our cohort was lower for
black patients than for white/other patients (1.28 [95%
confidence interval (CI), 1.14-1.44] vs 1.71 [95% CI,
1.63-1.80] per 100 person-years). Table 2 lists hazard
ratios for death for patients stratified by baseline
eGFR. In unadjusted analyses using eGFR of 90-104
mL/min/1.73 m2 as the reference category, eGFR
60 or105 mL/min/1.73 m2 at baseline was associ-
ated with increased mortality. Adjustment for demo-
graphic and HIV-associated parameters attenuated the
associations between decreased eGFR and all-cause
mortality, with only the eGFR categories 105 and
45 mL/min/1.73 m2 associated significantly with
death (Table 2). The association between eGFR and
mortality was U-shaped, with both lower and upper
ends of eGFR associated with increased mortality
(Fig 2). In view of a statistically significant (P 
0.001) interaction between eGFR and ethnicity, we
repeated the analysis stratified by ethnicity (Table S1,
Table 2. Mortality Rates by eGFR Category and A
Baseline eGFR Eventsa HR (95
105 mL/min/1.73 m2 703/41,385 1.15 (1.0
90-104 mL/min/1.73 m2 502/34,862 1.00 (refe
60-89 mL/min/1.73 m2 520/33,838 1.08 (0.9
45-59 mL/min/1.73 m2 56/1,465 2.65 (2.0
30-44 mL/min/1.73 m2 15/257 3.88 (2.3
30 mL/min/1.73 m2 24/260 5.75 (3.8
Note: A statistically significant interaction (P 0.001) between
Abbreviations: CI, confidence interval; eGFR, estimated glome
aReported per person-years of follow-up.
bAdjusted for age, sex, ethnicity, risk group, and years sinc
combination antiretroviral therapy use, AIDS, hepatitis B surfaceavailable as online supplementary material). The U-
542shaped relationship was present in patients of both
black and white/other ethnicity, with a more pro-
nounced increase in mortality risk with decreasing
eGFR in black patients.
Baseline eGFRandProgression to Stages 4-5CKD
By the end of the study period, 118 (0.6%) patients
had stages 4-5 CKD. In 62 of these patients (53%),
stages 4-5 CKD were already established at baseline.
Patients with stages 4-5 CKD had a median age of 38
(25th-75th percentile, 33-45) years, were predomi-
nantly male (69%) and of black ethnicity (54%), had
low rates of hepatitis B or C coinfection (9% and 4%,
respectively), and had more advanced immunodefi-
iation of eGFR Category With All-Cause Mortality
Crude Adjustedb
P HR (95% CI) P
0) 0.01 1.31 (1.17-1.47) 0.001
e) 1.00 (reference)
2) 0.2 0.92 (0.81-1.04) 0.2
0) 0.001 1.34 (0.95-1.89) 0.09
8) 0.001 1.70 (1.06-2.72) 0.03
6) 0.001 3.08 (1.95-4.88) 0.001
R and ethnicity was present.
filtration rate; HR, hazard ratio.
ry into the cohort; as well as CD4 cell count, HIV RNA level,
en, and hepatitis C antibody status as time-updated covariates.
Figure 2. Hazard ratios (HRs) and 95% confidence inter-
vals (CIs) for all-cause mortality and estimated glomerular filtra-
tion rate (eGFR) categories according to spline. Data were
adjusted for age, sex, ethnicity, risk group, and years since entry
into the cohort as fixed covariates and CD4 cell count, HIV
(human immunodeficiency virus) RNA level, combination antiret-
roviral therapy use, AIDS, and hepatitis B surface antigen and
hepatitis C antibody status as time-updated covariates. The
diamond symbol represents the reference point of eGFR of 95
mL/min/1.73 m2ssoc
% CI)
3-1.3
renc
5-1.2
1-3.5
2-6.4
1-8.6
eGF
rular
e ent(knots at eGFRs of 45, 60, 75, 90, and 105
mL/min/1.73 m2).
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Kidney Disease Progression in HIV Infectionciency at baseline (median CD4 cell count, 213 [25th-
75th percentile, 93-365] cells/L compared with 348
[25th-75th percentile, 203-520] cells/L in those not
categorized as CKD stages 4-5).
To examine the relationship between baseline eGFR
and kidney disease progression, we used Cox models
that allowed adjustments for the competing risk of
death. Standard time-to-event analyses assume that
censoring over time (drop out of the study over time)
is independent of both exposure and outcome. For
kidney disease progression, these models would as-
sume that deaths are independent of kidney disease
and, because our previous analyses have shown that
the exposure of interest (eGFR) and ethnicity are
predictors of death, thus may be biased. The compet-
ing-risk model allows for death to be correlated with
kidney disease progression; in other words, the fitted
model allows for kidney disease progressors to have a
higher mortality risk. Hence, we used competing-risk
models, and results for the association of eGFR with
kidney disease progression are expressed as subhaz-
ard ratios.
All 20,045 patients with eGFR 30 mL/min/1.73
m2 at baseline were included in the competing-risk
regression analysis. Median number of available eGFR
determinations was 18 (25th-75th percentile, 8-32)
per patient and median interval between measure-
ments was 3.5 (25th-75th percentile, 2.3-5.6) months.
Progression to stages 4-5 CKD was observed in 0.1%,
0.33%, 3.5%, and 23.1% of patients with baseline
eGFR 90, 60-89, 45-59, and 30-44 mL/min/1.73
m2, respectively, with a median interval of 1.39 (25th-
75th percentile, 0.18-4.59) years between baseline
and the first sustained eGFR 30 mL/min/1.73 m2.
Progression to stages 4-5 CKD was more frequent in
black compared with white/other patients (crude inci-
dence rates of 0.92 [95% CI, 0.61-1.39] vs 0.33 [95%
Table 3. Association of Baseline eGFR C
Baseline eGFR No. of eGFRsa Eventsb
90 mL/min/1.73 m2 17 [7, 31] 14/84,853 1
60-89 mL/min/1.73 m2 20 [8, 34] 18/37,763 2
45-59 mL/min/1.73 m2 23 [10, 41] 9/1,797 2
30-44 mL/min/1.73 m2 18 [12, 41] 15/317 28
Note: Analysis adjusted for competing end point of all-cause m
Abbreviations: CI, confidence interval; CKD, chronic kidney dis
hazard ratio.
aTotal number of times eGFR was determined during follow-up
bReported per person-years of follow-up.
cAdjusted for age, sex, risk group, ethnicity, years since e
antiretroviral therapy use, and AIDS; as well as hepatitis B surfac
taken at same time as the baseline eGFR).CI, 0.23-0.46] per 1,000 person-years; rate ratio, 2.8
Am J Kidney Dis. 2012;60(4):539-547[95% CI, 1.6-4.8]; P  0.001), and increased from
0.16 (95% CI, 0.09-0.28) to 0.47 (95% CI, 0.30-0.75),
5.0 (95% CI, 2.61-9.62), and 47.4 (95% CI, 28.58-
78.62) per 1,000 person-years in patients with base-
line eGFR 90, 60-89, 45-59, and 30-44 mL/min/
1.73 m2, respectively. Interestingly, the incidence of
stages 4-5 CKD in patients with eGFR of 60-89
mL/min/1.73 m2 at baseline was nearly 10-fold higher
in black compared with white/other patients (2.13 vs
0.24/1,000 person-years).
In both unadjusted and adjusted analyses, baseline
eGFR was associated strongly with progression to
stages 4-5 CKD (Table 3). The association of eGFR
with kidney disease progression differed by ethnicity
(Table 4). In black patients, the subhazard ratio for
progression to stages 4-5 CKD increased with decreas-
ing baseline eGFR 90 mL/min/1.73 m2, whereas in
white/other patients, the association with progression
was detectable only with decreasing baseline eGFR
60 mL/min/1.73 m2. These hazards were affected
minimally by adjustment for demographic and HIV-
associated parameters. However, the absolute risk of
stages 4-5 CKD in black patients with eGFR of 60-89
mL/min/1.73 m2 and white/other patients with eGFR
of 45-59 mL/min/1.73 m2 was low (2.1 and 2.6
events/1,000 person-years). In contrast, high rates of
progression to stages 4-5 CKD were observed in black
patients with eGFR of 30-59 mL/min/1.73 m2 and
white/other patients with eGFR of 30-44 mL/min/
1.73 m2 (31.1 and 37.0 events/1,000 person-years,
respectively).
DISCUSSION
In this large HIV cohort, we observed an indepen-
dent U-shaped relationship between baseline eGFR
and mortality, with the highest risk in those with
stages 4-5 CKD at baseline. In addition, in analyses
ory With Progression to Stages 4-5 CKD
Crude Adjustedc
(95% CI) P SHR (95% CI) P
eference) 1.00 (reference)
.47-5.92) 0.002 3.51 (1.57-7.86) 0.002
2.9-69.2) 0.001 39.0 (15.0-101.3) 0.001
32.8-592.5) 0.001 361.3 (151.1-864.3) 0.001
ty.
; eGFR, estimated glomerular filtration rate; SHR, subdistribution
ludes baseline); values given as median [25th, 75th percentile].
into the cohort, CD4 cell count, HIV RNA level, combination
tigen and hepatitis C antibody status at baseline (measurementsateg
SHR
.00 (r
.95 (1
9.9 (1
0.5 (1
ortali
ease
(exc
ntry
e anthat adjusted for the competing mortality risk, base-
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Ibrahim et alline eGFR was an important predictor of kidney
disease progression. Decreased eGFR at baseline was
of much greater prognostic significance in black pa-
tients in terms of both death and kidney disease
progression. With incidence rates of stages 4-5 CKD
3%, black patients with eGFR of 30-59 mL/min/
1.73 m2 and white/other patients with eGFR of 30-44
mL/min/1.73 m2 at baseline should be investigated,
monitored carefully, and considered for targeted inter-
ventions to slow the decrease in kidney function.
Several studies have examined the effect on mortal-
ity when patients have decreased kidney function
prior to the initiation of cART. In HIV-positive women,
prevalent CKD, defined as eGFR 60 mL/min/1.73
m2 at 2 consecutive visits, was an independent risk
factor for death.27 In a large African cohort from
Zambia, eGFR 90 mL/min/1.73 m2 prior to initia-
tion of cART was associated with increased risk of
death, with the highest risk in those with eGFR 30
mL/min/1.73 m2,28 whereas in the FRAM (Fat Redis-
tribution and Metabolic Change in HIV) Study, a
creatinine-based eGFR 60 mL/min/1.73 m2 was
associated with death in only univariate analysis.29
Although these studies have clearly demonstrated a
relationship between decreased eGFR and mortality,
the observed association was attenuated in analyses
that were able to adjust for diabetes or hypertension27
or albuminuria, smoking, dyslipidemia, and body mor-
phology.29
In the Zambian study, more than half of all deaths
were observed in the first 3 months from cohort
entry.28 Decreased eGFR prior to initiation of cART
may reflect both acute kidney injury and CKD.11,38
Changes in eGFR are observed predominantly during
early exposure to cART, with stabilization of kidney
function after 4 weeks.39 Consequently, we ex-
cluded kidney function data and deaths that occurred
within the first 3 months of HIV diagnosis, and our
Table 4. Association of Baseline eGFR Category W
eGFRa
Black
Eventsb
Crude Adjustedc
SHR (95% CI) P SHR (95% CI)
90 2/19,822 1.00 (reference) 1.00 (reference)
60-89 10/4,699 21.8 (4.7-100.0) 0.001 26.4 (4.7-148.9)
45-59 5/280 177.4 (33.0-954.0) 0.001 196.7 (31.5-1,229.4)
30-44 6/74 730.2 (155.8-3,423.5) 0.001 1,163.4 (217.0-6,237.6
Note: Analysis adjusted for competing end point of all-cause mortality.
Abbreviations: CI, confidence interval; CKD, chronic kidney disease; eG
aeGFR at baseline (given in mL/min/1.73 m2).
bReported per person-years of follow-up.
cAdjusted for age, sex, risk group, years since entry into the cohort, C
antiretroviral therapy use, and AIDS, as well as hepatitis B surface antigenestimates of baseline eGFR are likely to reflect kidney
544function in the steady state. Consistent with results
from the FRAM Study,29 we observed no association
between eGFR of 30-59 mL/min/1.73 m2 and mortal-
ity in a predominantly white cohort of more than
15,000 patients.
We observed a U-shaped relationship between eGFR
and death. Consistent with observations in the general
population,21 mortality was lowest in patients with
eGFR of 90-105 mL/min/1.73 m2, whereas those with
eGFR 105 mL/min/1.73 m2 were at significantly
increased risk of death. However, eGFR prediction
equations are inaccurate at high eGFRs, and high
eGFR may reflect glomerular hyperfiltration44 or ill
health in patients with decreased muscle mass.21,45
This is supported by the linear relationship between
an alternative marker of kidney function, cystatin C
(which does not depend on muscle mass), and mortal-
ity.21
The risk of kidney disease progression in HIV-
positive black patients is increased,32,46-49 and recent
genetic studies implicate the APOL1 G1 and G2
alleles to account in part for this excess of risk.50-52
However, the absolute risk of stages 4-5 CKD in this
population was low, with 1% of participants in our
study reaching this end point. Consistent with our
earlier studies of HIV-associated kidney disease,11,33
more than half of those with stages 4-5 CKD already
had eGFR 30 mL/min/1.73 m2 at baseline, and
many of these patients are likely to have had irrevers-
ible kidney damage at the time of HIV diagnosis.11
Data for the role of cART in kidney disease progres-
sion are conflicting; several antiretrovirals, including
tenofovir, indinavir, and atazanavir, have been associ-
ated with kidney disease progression.26,53 However,
immunodeficiency, HIV viremia, and nonuse of cART
are common factors in patients with stages 4-5
CKD,11,33,54,55 and the use of cART and suppression
of HIV RNA may improve kidney function,56 reduce
ogression to Stages 4-5 CKD, Stratified by Ethnicity
White/Other
Eventsb
Crude Adjustedc
SHR (95% CI) P SHR (95% CI) P
12/65,031 1.00 (reference) 1.00 (reference)
001 8/33,064 1.3 (0.5-3.2) 0.5 1.2 (0.5-3.1) 0.7
001 4/1,517 13.9 (4.6-42.1) 0.001 16.2 (4.2-62.1) 0.001
001 9/243 194.5 (78.0-485.1) 0.001 217.7 (63.7-743.5) 0.001
stimated glomerular filtration rate; SHR, subdistribution hazard ratio.
ell count, HIV (human immunodeficiency virus) RNA level, combination
epatitis C antibody status at baseline.ith Pr
P
0.
0.
) 0.
FR, ethe rate of eGFR decrease,57 or reduce the risk of
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Kidney Disease Progression in HIV Infectionrenal events.58 Our data suggest that in addition to
these factors, baseline eGFR is helpful in assessing
the risk of developing stages 4-5 CKD in HIV-
positive patients.
The strengths of this study include the large sample
size and prolonged follow-up. However, this study
was conducted in a population at relatively low risk of
CKD (predominately white and with a low hepatitis C
prevalence). Limitations therefore include the rela-
tively small numbers of patients with decreased eGFR
at baseline and the low rates of progression to stages
4-5 CKD, limiting the power of the study and result-
ing in large 95% CIs around point estimates in the
competing-risk analysis. We are unable to account for
loss to follow-up, including those referred to clinics
not participating in CHIC. Furthermore, we lacked
data for cardiovascular and renal risk factors, such as
diabetes, hypertension, and proteinuria; a reliable indi-
cator of muscle mass; clinical status; socioeconomic
status; and information for cause of death. Finally, we
have not accounted for small differences in creatinine
calibration between contributing laboratories.
In summary, our results show that decreased eGFR
at baseline is an independent risk factor for all-cause
mortality and progression to stages 4-5 CKD. The low
rates of kidney disease progression observed in our
cohort are explained at least in part by considerable
competing mortality. Our results highlight the impor-
tance of early HIV diagnosis because stages 4-5 CKD
were already established at baseline in most patients.
Because black HIV-positive patients with eGFR of 30-59
mL/min/1.73 m2 and white/other HIV-positive patients
with eGFR of 30-44 mL/min/1.73 m2 were at high risk
of kidney disease progression, their eGFR should be
monitored closely during clinical follow-up.
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